Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Joel M Baumgartner
Affiliation
University of California
ORCID
Career Start Year
2007
Papers
81
H Index
24
Expertise
CM4AI Collaborator
Trey Ideker (CM4AI)
PMID
Paper Title
Journal Title
Published Year
37436640
Role of Circulating Tumor DNA Among Patients with Colorectal Peritoneal Metastases.
J Gastrointest Cancer
2024
37806228
Weekend Discharge Is Not Associated With Increased Readmission After Hyperthermic Intraperitoneal Chemotherapy.
J Surg Res
2024
36305990
Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?
Ann Surg Oncol
2023
37666090
Prediction of Early Recurrence Following CRS/HIPEC in Patients With Disseminated Appendiceal Cancer.
J Surg Res
2023
37620532
Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy.
Ann Surg Oncol
2023
37423927
ASO Visual Abstract: Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Multi-institutional Analysis.
Ann Surg Oncol
2023
37294386
Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-institutional Analysis.
Ann Surg Oncol
2023
36477643
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis.
Surg Endosc
2023
36468401
Influence of insurance status on the postoperative outcomes of cytoreductive surgery and HIPEC.
J Surg Oncol
2023
36369408
ASO Visual Abstract: Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?
Ann Surg Oncol
2023
36367628
ASO Author Reflections: Routine Omentectomy During Cytoreductive Surgery and HIPEC.
Ann Surg Oncol
2023
34506026
Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative.
J Gastrointest Surg
2022
35849291
Co-Localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series.
Ann Surg Oncol
2022
36571414
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens.
J Vis Exp
2022
36102565
Alvimopan for Enhanced Gastrointestinal Recovery after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Randomized Controlled Trial.
J Am Coll Surg
2022
36067351
An Ex Vivo Organotypic Culture Platform for Functional Interrogation of Human Appendiceal Cancer Reveals a Prominent and Heterogenous Immunological Landscape.
Clin Cancer Res
2022
36064993
ASO Visual Abstract: Co-localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series.
Ann Surg Oncol
2022
33002202
A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC.
J Surg Oncol
2021
33905776
Ki67 does not predict recurrence for low-grade appendiceal mucinous neoplasms with peritoneal dissemination after cytoreductive surgery and HIPEC.
Hum Pathol
2021
33845460
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
J Natl Compr Canc Netw
2021
33507449
Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis.
Ann Surg Oncol
2021
33634422
The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative.
J Gastrointest Surg
2021
34994628
Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal Origin.
JCO Precis Oncol
2021
33465587
A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies.
Surg Oncol
2021
33415564
A Multi-institutional Study of Peritoneal Recurrence Following Resection of Low-grade Appendiceal Mucinous Neoplasms.
Ann Surg Oncol
2021
31428960
Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.
J Gastrointest Surg
2020
31745888
Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study.
J Gastrointest Surg
2020
31659645
Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?
Ann Surg Oncol
2020
31974019
What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative.
Clin Colorectal Cancer
2020
33270763
Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
PLoS One
2020
33073341
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative.
Ann Surg Oncol
2020
33040617
The impact of HIPEC <i>vs.</i> EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative.
Int J Hyperthermia
2020
32864043
Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative.
World J Gastrointest Oncol
2020
32767050
Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
Ann Surg Oncol
2020
32627199
Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways.
J Surg Oncol
2020
32622162
Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
J Surg Res
2020
32696303
Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative.
Ann Surg Oncol
2020
32303875
ASO Author Reflections: Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
Ann Surg Oncol
2020
32164300
Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review.
J Clin Med
2020
32318945
Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study.
Ann Surg Oncol
2020
31558307
Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Am J Surg
2020
30815802
Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?
Ann Surg Oncol
2019
30132292
Tumor Symbiosis: Gastrointestinal Stromal Tumor as a Host for Primary Peritoneal Mesothelioma.
J Gastrointest Surg
2019
31576472
ASO Author Reflections: Venous Thromboembolism after CRS/HIPEC.
Ann Surg Oncol
2019
31190209
Obstruction-Free Survival Following Operative Intervention for Malignant Bowel Obstruction in Appendiceal Cancer.
Ann Surg Oncol
2019
31016486
Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study.
Ann Surg Oncol
2019
31065960
Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Ann Surg Oncol
2019
29090402
Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
Ann Surg Oncol
2018
32913983
Genomic Landscape of Appendiceal Neoplasms.
JCO Precis Oncol
2018
29948422
Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
Ann Surg Oncol
2018
1 - 50 of 81
Column Actions
Search
Recommended Authors
Ian Solsky
Wake Forest University
Career Start Year
2015
Number of shared co-authors
0
Alex B Blair
Johns Hopkins University School of Medicine
Career Start Year
2015
Number of shared co-authors
0
Ian W Folkert
Perelman School of Medicine, University of Pennsylvania
Career Start Year
2015
Number of shared co-authors
0
Nazim Benzerdjeb
Institut de Pathologie Multisite
Career Start Year
2013
Number of shared co-authors
0
Hiroyuki Horiguchi
National Defense Medical College
Career Start Year
2012
Number of shared co-authors
0
Nicholas Brian Shannon
Singapore General Hospital
Career Start Year
2010
Number of shared co-authors
0
Liang Cao
National Cancer Institute, National Institutes of Health
Career Start Year
2008
Number of shared co-authors
0
Patricio M Polanco
University of Texas Southwestern Medical Center
Career Start Year
2006
Number of shared co-authors
1
Samuel Eisenstein
University of California San Diego
Career Start Year
2004
Number of shared co-authors
2
Rebecca C Auer
The Ottawa Hospital Research Institute
Career Start Year
2002
Number of shared co-authors
0
Brian A Costello
The Mayo Clinic
Career Start Year
2001
Number of shared co-authors
2
Itzhak Avital
Goldman School of Medicine, Ben Gurion University
Career Start Year
2001
Number of shared co-authors
0
Scott Kopetz
University of Texas MD Anderson Cancer Center
Career Start Year
2000
Number of shared co-authors
6
Thomas J George
UF Health Cancer Center
Career Start Year
1998
Number of shared co-authors
3
Isabelle Ray-Coquard
University Claude Bernard Lyon I
Career Start Year
1997
Number of shared co-authors
0
Antonio Cubillo
Hospital HM Universitario Sanchinarro
Career Start Year
1997
Number of shared co-authors
0
Helgi Birgisson
The Icelandic Cancer Registry
Career Start Year
1997
Number of shared co-authors
0
Victor M Zaydfudim
Surgical Outcomes Research Center, University of Virginia
Career Start Year
1996
Number of shared co-authors
0
Alexandra M Easson
University of Toronto
Career Start Year
1996
Number of shared co-authors
0
Udo Rudloff
Center for Cancer Research, National Cancer Institute
Career Start Year
1994
Number of shared co-authors
0
Hideki Ueno
National Defense Medical College
Career Start Year
1993
Number of shared co-authors
1
John M Kane
Roswell Park Comprehensive Cancer Center
Career Start Year
1993
Number of shared co-authors
2
Kerrington D Smith
Dartmouth-Hitchcock Medical Center
Career Start Year
1991
Number of shared co-authors
1
Oliver F Bathe
Cumming School of Medicine, University of Calgary
Career Start Year
1991
Number of shared co-authors
0
Charles R Thomas
Oregon Health & Science University
Career Start Year
1990
Number of shared co-authors
1
Richard J Barth
Dartmouth-Hitchcock Medical Center
Career Start Year
1990
Number of shared co-authors
0
Steven R Alberts
Mayo Clinic
Career Start Year
1987
Number of shared co-authors
2
Al B Benson
Northwestern University Feinberg School of Medicine
Career Start Year
1984
Number of shared co-authors
8
Richard D Schulick
University of Colorado School of Medicine
Career Start Year
1983
Number of shared co-authors
2
Cornelis J H van de Velde
Leiden University Medical Center: Leids Universitair Medisch Centrum.
Career Start Year
1977
Number of shared co-authors
0
row(s) 1 - 30 of 30
Collaborators
Andrew M Lowy
University of California San Diego
Co-authored papers
30
Martin D McCarter
University of Colorado School of Medicine
Co-authored papers
7
Rebecca A Marmor
12220University of California San Diego
Co-authored papers
4
Syed A Ahmad
University of Cincinnati College of Medicine
Co-authored papers
4
Mark A Valasek
Co-authored papers
4
Lisa Madlensky
Department of Medicine and Moores Cancer Center, University of California San Diego.
Co-authored papers
3
Olivier Harismendy
University of California
Co-authored papers
3
Paul T Fanta
University of California San Diego Moores Cancer Center
Co-authored papers
3
William A Robinson
National Centre for Asbestos Related Diseases, University of Western Australia
Co-authored papers
2
Erin Ward
Boston Children's Hospital
Co-authored papers
2
Christopher C Silliman
Vitalant Research Institute
Co-authored papers
2
Santiago González-Moreno
Co-authored papers
2
Sonia Ramamoorthy
University of California
Co-authored papers
2
Karen Messer
Herbert Wertheim School of Public Health, University of California San Diego
Co-authored papers
2
Rene Gonzalez
University of Colorado Anschutz Medical Campus
Co-authored papers
2
Beatrice J Edwards
Central Texas Veterans Healthcare System
Co-authored papers
1
Anna Weiss
Co-authored papers
1
Michael A Liss
University of Texas Health San Antonio
Co-authored papers
1
Daniel T Laskowitz
Duke University
Co-authored papers
1
Maria Elena Martinez
Co-authored papers
1
Celina Ang
Tisch Cancer Institute, Mount Sinai Hospital
Co-authored papers
1
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Co-authored papers
1
Michael Bouvet
Co-authored papers
1
David Xu
Co-authored papers
1
John Paul Shen
The University of Texas MD Anderson Cancer Center
Co-authored papers
1
Kimberly R Jordan
University of Colorado Anschutz Medical Campus
Co-authored papers
1
June M McKoy
Feinberg School of Medicine, Northwestern University
Co-authored papers
1
Bruno C Medeiros
AbbVie Inc.
Co-authored papers
1
Ann Tipps
University of California San Diego
Co-authored papers
1
Florin Vaida
School of Public Health, university of california san diego
Co-authored papers
1
1 - 30